Phase 1 Study of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine in Healthy Adults

Phase 1, open-label trial of fluticasone propionate in human immunodeficiency virus infection (HIV) (8 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness at 7 days, Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration at 7 days and 11 more. Started Aug 2022; status: terminated.